Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Pancreatic Neoplasms 1Lung Neoplasms 1Carcinoma, Endometrioid 1Adenocarcinoma of Lung 1

Interventions

Carboplatin 6Radiotherapy 5Radiation 4Nivolumab 4Magnetic Resonance Spectroscopy 4Specimen Handling 3Pemetrexed 3Biopsy 3Bevacizumab 3capmatinib 2Radiotherapy, Conformal 2Platinum 2Paclitaxel 2Ipilimumab 2Immunoglobulin G 2Disulfides 2Cisplatin 2CTLA-4 Antigen 21,2-diaminocyclohexaneplatinum II citrate 2veliparib 1pembrolizumab 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1osimertinib 1methoxyamine 1lazertinib 1fludarabine phosphate 1durvalumab 1defactinib 1atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma of Lung × RO5126766 × 90 days × Clear all
NCT06495125 2026-04-06

Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer

Emory University

Phase 2 Recruiting
50 enrolled
Thoracic

Adenocarcinoma of Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡